Home |About NASCSA | Bylaws | Exec Committee | Links |Membership-Sponsorship
Member States | Newsletters | Pictures | Resolutions | Prescription Monitoring | State Contacts | Sponsors | State Profiles
Home
|About NASCSA |
Bylaws |
Exec
Committee | Links |Membership-Sponsorship
Member States |
Newsletters |
Pictures |
Resolutions
| Prescription Monitoring
| State Contacts |
Sponsors
| State Profiles
You may narrow your view of news articles by clicking the "Search by Category" button at the top left of the page and you may also search using "Keywords". All news irems are archived based on a pre-determined date and will then appear in the "Archives" section of the page. You may access the archives by clicking the "Archives" button and once in that area may return to the primary news area by clicking the "Current" button. Once you open an article by clicking the item's title or selecting "view", you may email a link to that news page by clicking on "Send to Friend" and completing the e-mailing form
NASCSA News:
Friday, September 10, 2010
|
| Show All » NEWS of NOTE » General » | |||||||||||||||||||||||||||||||||||||||||
|
FDA Formally Approves Onsolis - July 17, 2009
Link to this article: http://triangle.bizjournals.com/triangle/stories/2009/07/13/daily53.html?surround=etf Thursday, July 16, 2009, 4:12pm FDA Approval Pumps $27M into Bio Delivery Sciences International pipeline Triangle Business Journal The U.S. Food and Drug Administration on Thursday formally approved Onsolis, Raleigh-based BDSI's mouth patch that delivers the painkilling drug fentanyl to cancer patients suffering severe “breakthrough pain” that doesn't respond to other medications. Onsolis is manufactured by Aveva Drug Delivery Systems of Florida and marketed under license from BDSI (Nasdaq: BDSI) by Meda Pharmaceuticals. With FDA approval of Onsolis, BDSI is due about $27 million in milestone payments, which Sirgo said would be directed to the company's drug pipeline. T o read complete article click on link at top of page « Go Back |
|||||||||||||||||||||||||||||||||||||||||
|